Toxicity and virucidal activity of a neon-driven micro plasma jet on eukaryotic cells and a coronavirus.
Cold physical plasma
Gas plasma technology
MHV
Murine hepatitis virus
ROS
Reactive oxygen species
Virus inactivation
Journal
Free radical biology & medicine
ISSN: 1873-4596
Titre abrégé: Free Radic Biol Med
Pays: United States
ID NLM: 8709159
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
22
04
2022
revised:
06
08
2022
accepted:
15
08
2022
pubmed:
31
8
2022
medline:
5
10
2022
entrez:
30
8
2022
Statut:
ppublish
Résumé
Plasma medicine is a developing field that utilizes the effects of cold physical plasma on biological substrates for therapeutic purposes. Approved plasma technology is frequently used in clinics to treat chronic wounds and skin infections. One mode of action responsible for beneficial effects in patients is the potent antimicrobial activity of cold plasma systems, which is linked to their unique generation of a plethora of reactive oxygen and nitrogen species (ROS). During the SARS-CoV-2 pandemic, it became increasingly clear that societies need novel ways of passive and active protection from viral airway infections. Plasma technology may be suitable for superficial virus inactivation. Employing an optimized neon-driven micro plasma jet, treatment time-dependent ROS production and cytotoxic effects to different degrees were found in four different human cell lines with respect to their metabolic activity and viability. Using the murine hepatitis virus (MHV), a taxonomic relative of human coronaviruses, plasma exposure drastically reduced the number of infected murine fibroblasts by up to 3000-fold. Direct plasma contact (conductive) with the target maximized ROS production, cytotoxicity, and antiviral activity compared to non-conductive treatment with the remote gas phase only. Strikingly, antioxidant pretreatment reduced but not abrogated conductive plasma exposure effects, pointing to potential non-ROS-related mechanisms of antiviral activity. In summary, an optimized micro plasma jet showed antiviral activity and cytotoxicity in human cells, which was in part ROS-dependent. Further studies using more complex tissue models are needed to identify a safe dose-effect window of antiviral activity at modest toxicity.
Identifiants
pubmed: 36041652
pii: S0891-5849(22)00554-8
doi: 10.1016/j.freeradbiomed.2022.08.026
pmc: PMC9420207
pii:
doi:
Substances chimiques
Antioxidants
0
Antiviral Agents
0
Plasma Gases
0
Neon
4VB4Y46AHD
Nitrogen
N762921K75
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-118Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflict of interest to declare.
Références
Sci Rep. 2017 Apr 4;7(1):600
pubmed: 28377599
Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):582-7
pubmed: 19124777
IEEE Trans Radiat Plasma Med Sci. 2020 Jun 16;4(4):391-399
pubmed: 34192214
Sci Rep. 2019 Jul 23;9(1):10637
pubmed: 31337782
Mol Cell Biochem. 2002 May-Jun;234-235(1-2):185-93
pubmed: 12162432
Chem Phys Lipids. 2020 Jan;226:104786
pubmed: 31229410
Br J Cancer. 2016 Feb 16;114(4):435-43
pubmed: 26882067
Mol Cell Biol. 2000 Dec;20(23):8969-82
pubmed: 11073996
Sci Rep. 2018 May 16;8(1):7736
pubmed: 29769633
Curr Protoc Microbiol. 2011 May;Chapter 15:Unit 15E.1
pubmed: 21538303
Viruses. 2019 Oct 16;11(10):
pubmed: 31623281
J Virol Methods. 2008 Oct;153(1):74-7
pubmed: 18598719
Chem Sci. 2016 Jan 1;7(1):489-498
pubmed: 28791102
Biointerphases. 2020 Nov 25;15(6):061008
pubmed: 33238712
Front Nutr. 2021 Jun 08;8:628723
pubmed: 34169086
J Gen Virol. 2020 Feb;101(2):208-215
pubmed: 31961788
Cells. 2021 Oct 28;10(11):
pubmed: 34831159
J Immunol Methods. 2016 Mar;430:10-20
pubmed: 26780292
Cell Death Dis. 2016 Apr 21;7:e2199
pubmed: 27100893
PLoS One. 2017 May 24;12(5):e0178220
pubmed: 28542462
BMC Cancer. 2012 Oct 15;12:473
pubmed: 23066891
Phys Chem Chem Phys. 2019 Sep 21;21(35):19327-19341
pubmed: 31453592
Free Radic Biol Med. 2021 May 1;167:12-28
pubmed: 33711420
Sci Rep. 2017 Jul 18;7(1):5761
pubmed: 28720839
Biointerphases. 2015 Dec 22;10(4):040801
pubmed: 26700469
Process Saf Environ Prot. 2021 Nov;155:230-261
pubmed: 34566275
Nat Rev Genet. 2009 Apr;10(4):252-63
pubmed: 19274049
Free Radic Biol Med. 2016 Aug;97:14-23
pubmed: 27208785
Theranostics. 2022 Mar 14;12(6):2811-2832
pubmed: 35401827
Adv Sci (Weinh). 2021 Mar 08;8(10):2003395
pubmed: 34026437
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
J Med Virol. 2017 Jun;89(6):952-959
pubmed: 27696466
Cancer Res. 2001 Nov 15;61(22):8051-7
pubmed: 11719426
Front Microbiol. 2021 Oct 12;12:737635
pubmed: 34712211
Environ Sci Pollut Res Int. 2022 Jan;29(4):4880-4892
pubmed: 34796437
Theranostics. 2019 Sep 21;9(23):6920-6935
pubmed: 31660077
F1000Res. 2018 Mar 2;7:260
pubmed: 29568499
Sci Rep. 2021 Jan 8;11(1):136
pubmed: 33420228
Curr Med Sci. 2018 Feb;38(1):107-114
pubmed: 30074159
Biomedicines. 2021 Sep 18;9(9):
pubmed: 34572443
Rev Clin Esp (Barc). 2021 Jan;221(1):55-61
pubmed: 33998479
J Appl Microbiol. 2017 Aug;123(2):308-324
pubmed: 28245092
Apoptosis. 2021 Aug;26(7-8):385-414
pubmed: 34236569
Front Cell Infect Microbiol. 2020 Jun 05;10:317
pubmed: 32582574
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200708119
pubmed: 35901213
Mol Biol Cell. 1999 Feb;10(2):361-72
pubmed: 9950682
Trends Biotechnol. 2020 Nov;38(11):1278-1291
pubmed: 32418663
J Phys D Appl Phys. 2019 Jun 19;52(25):255201
pubmed: 32287389
Free Radic Biol Med. 2022 Feb 20;180:210-219
pubmed: 35065239
Pathogens. 2020 Sep 08;9(9):
pubmed: 32911671
Antioxidants (Basel). 2022 Jul 25;11(8):
pubmed: 35892641
Anticancer Res. 2012 Jul;32(7):2599-624
pubmed: 22753718
Nat Rev Mol Cell Biol. 2022 Jul;23(7):499-515
pubmed: 35190722
Redox Biol. 2021 Oct;46:102116
pubmed: 34474394
Biochim Biophys Acta. 2013 Aug;1833(8):2016-28
pubmed: 23583303
Antimicrob Resist Infect Control. 2020 Jul 6;9(1):100
pubmed: 32631450